Bimodal degradation of MLL by SCF^{Skp2} and APC^{Cdc20} assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions

Han Liu,^{1,2} Emily H.-Y. Cheng,^{1,2,3} and James J.-D. Hsieh^{1,2,4,5}

¹Molecular Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA;

²Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA; ³Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA; ⁴Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110, USA

Human chromosome 11q23 translocations disrupting *MLL* result in poor prognostic leukemias. It fuses the common MLL N-terminal ~1400 amino acids in-frame with >60 different partners without shared characteristics. In addition to the well-characterized activity of MLL in maintaining *Hox* gene expression, our recent studies established an MLL–E2F axis in orchestrating core cell cycle gene expression including *Cyclins*. Here, we demonstrate a biphasic expression of MLL conferred by defined windows of degradation mediated by specialized cell cycle E3 ligases. Specifically, SCF^{Skp2} and APC^{Cdc20} mark MLL for degradation at S phase and late M phase, respectively. Abolished peak expression of MLL incurs corresponding defects in G1/S transition and M-phase progression. Conversely, overexpression of MLL blocks S-phase progression. Remarkably, MLL degradation initiates at its N-terminal ~1400 amino acids, and tested prevalent MLL fusions are resistant to degradation. Thus, impaired degradation of MLL fusions likely constitutes the universal mechanism underlying all MLL leukemias. Our data conclude an essential post-translational regulation of MLL by the cell cycle ubiquitin/proteasome system (UPS) assures the temporal necessity of MLL in coordinating cell cycle progression.

[**Keywords:** MLL; Taspase1; Skp2; Cdc20; cell cycle; leukemia]

Supplemental material is available at <http://www.genesdev.org>.

Received May 22, 2007; revised version accepted August 3, 2007.

The eukaryotic cell cycle consists of a tightly orchestrated circular progression of a sequence of distinct phases—namely, G1, S, G2, and M—designated for the execution of inherent genetic programs (Nurse 2000). Key regulatory components of the mammalian cell cycle machinery include E2Fs, Rbs, Cyclins, Cyclin-dependent kinases (CDKs), and CDK inhibitors (CDKIs), which form complex positive and negative epistatic circuits ensuring accurate cell cycle progression (Murray 2004). The molecular blueprint of a normal cell cycle details the central controls held by a series of CDKs that positively influences proliferation through phosphorylating target proteins such as Rbs (Morgan 1997). This releases the repressive activities of Rbs on E2Fs, the major executors of cell cycle gene expression programs (Dyson 1998; Nevins 2001; Trimarchi and Lees 2002; Blais and Dynlacht 2004; Bracken et al. 2004; Giacinti and Giordano

2006). Individual CDKs need to complex with specialized Cyclins to form catalytically active Cyclin/CDKs; therefore, their activities depend on the availability of involved Cyclins. Additional regulations of Cyclin/CDKs come from negative factors, the CDKIs (Sherr and Roberts 1999). Levels of Cyclins and CDKIs undulate during cell division, which in part is due to the defined windows of degradation by the ubiquitin–proteasome system (UPS) (Reed 2003). UPS commences at substrate recognition and the subsequent covalent conjugation of ubiquitin by the responsible E3 ligases, followed by degradation executed by the 26S proteasome (Hershko 2005). The two major E3 complexes involved in proteolyzing core components of the cell cycle machinery are SCF (Skp1–Cul1–F-box protein) and APC (anaphase-promoting complex/cyclosome) complexes, the substrate recognition of which is conducted by the variable components—F-box proteins for SCF, and Cdc20 and Cdh1 for APC (Cardozo and Pagano 2004; Nakayama and Nakayama 2006; Peters 2006). Thus, two types of post-translational modifications—phosphorylation and

⁵Corresponding author.

E-MAIL jhsieh@im.wustl.edu; FAX (314) 362-1589.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1574507>.

ubiquitination—constitute the two mainstream controls of the cell cycle.

Polycomb group (PcG) and trithorax group (trxG) proteins are chromatin modifiers required for the epigenetic maintenance of repressive versus active states of cell fate specification genes (Schumacher and Magnuson 1997; Yu et al. 1998; Hanson et al. 1999; Ringrose and Paro 2004; Schuettengruber et al. 2007). The most-characterized targets are the *Hox* genes in vertebrates and *homeotic* genes in invertebrates. Beyond perpetuating cellular memory through multiple cell divisions, recent studies on mammals and flies highlighted the active, dynamic participation of PcG proteins in the transcriptional control of cell cycle genes such as the *p16^{Ink4a}/ARF* locus and *Cyclin A* (Jacobs et al. 1999a,b; Martinez and Cavalli 2006; Martinez et al. 2006). For example, Bmi-1 can function as an oncogene through its positive influence on cell proliferation by suppressing *p16^{Ink4a}* (Jacobs et al. 1999b). On the other hand, genetic evidence also supports certain PcG proteins, such as Mel-18, as tumor suppressors in that they negatively regulate proliferation (Guo et al. 2007). Despite ample elucidation on the intimate relationship between PcG and the cell cycle, we are only at the beginning in realizing a similar cell cycle duty carried out by the trxG members.

MLL, the mammalian ortholog of *Drosophila* trithorax, is the founding member of the trxG proteins (Gu et al. 1992; Tkachuk et al. 1992; Djabali et al. 1993; Domer et al. 1993; Thirman et al. 1993). Genetic studies confirmed the evolutionarily conserved role of trx/MLL in maintaining *homeotic/Hox* gene expression, therefore specifying segmental identity (Yu et al. 1995; Ringrose and Paro 2004). Recurrent human chromosome band 11q23 translocations disrupting *MLL* cause leukemias of poor prognosis. MLL leukemic cells carry pathognomonic MLL fusion proteins resulting from an in-frame fusion between the N-terminal ~1400 amino acids of MLL with a wide spectrum of translocation partners, ranging from nuclear transcription factors to cytoplasmic structural proteins (Rowley 1998; Ayton and Cleary 2001; Canaani et al. 2004; Daser and Rabbitts 2004; Gilliland et al. 2004; Hess 2004; Eguchi et al. 2005). As implicated by the broad diversity of translocation partners, elegant murine models specifically examined their possible dispensability and nonspecificity (Corral et al. 1996; Dobson et al. 2000; Wang et al. 2005). Remarkably, mice engineered to carry the *MLL-lacZ* but not the *MLL-Myc* tag allele developed leukemia, confirming the indispensability and, yet, nonspecificity of these partners (Dobson et al. 2000). Although certain shared properties have been recognized among some fusion partners (Slany et al. 1998; Martin et al. 2003; So et al. 2003), there is no universally applicable mechanism identified.

MLL encodes a 3969-amino-acid nuclear protein consisting of multiple conserved domains with distinct biological properties. The most well-characterized biochemical property of MLL is its ability to methylate histone H3 at Lys 4 through the conserved SET domain at the very C terminus (Milne et al. 2002; Nakamura et al. 2002). The complexity of *MLL* gene regulation was fur-

ther illustrated when we and others showed that the 500-kDa full-length MLL precursor (MLL^{FL}) undergoes evolutionarily conserved site-specific proteolysis to generate a mature MLL^{N320/C180} heterodimer, consisting of processed N-terminal 320-kDa and C-terminal 180-kDa fragments (Nakamura et al. 2002; Yokoyama et al. 2002; Hsieh et al. 2003b). Cleavage of MLL at QL(V)D/GXDD sites is mediated by Taspase1 (threonine aspartase 1) (Hsieh et al. 2003a), which is required for the full activity of MLL (Takeda et al. 2006). In other words, unprocessed MLL precursor functions as a hypomorphic allele (Takeda et al. 2006).

The discovery of Taspase1 initiated a novel class of endopeptidases that utilizes its N-terminal threonine of the mature β subunit to proteolyze substrates after an aspartate (Hsieh et al. 2003a). Taspase1 is translated as a proenzyme that undergoes autoproteolysis to generate a mature α/β heterodimer that displays an overall $\alpha/\beta/\alpha$ structure (Khan et al. 2005). In addition to its anticipated roles in *Hox* gene regulation, our recent studies on *Taspase1*^{-/-} mice linked MLL proteolysis to the heart of cell cycle gene programming (Takeda et al. 2006). We showed that MLL directly participates in cell cycle progression through an MLL–E2F axis that controls expression of *Cyclins E, A, and B*. In the absence of Taspase1, MLL remains as a precursor with reduced histone H3 K4 methyltransferase (HMT) activity (Takeda et al. 2006). Here we further examine how MLL controls the cell cycle and whether its activity is as tightly regulated as most of the key cell cycle regulators.

We provide evidence that MLL undergoes a specialized bimodal degradation resulting in its biphasic expression through the cell cycle. This unique expression is conferred by SCF^{Skp2} and APC^{Cdc20} E3 ligases of the cell cycle UPS. Importantly, deregulation of this organized expression, either through overexpression or knockdown, incurs corresponding cell cycle defects. Therefore, the observed biphasic appearance of MLL is essential in assuring the correct execution of inherent genetic programs underlying every single cell division. Our model predicts that tight control of MLL activity is essential in cell proliferation, and deregulated expression of MLL impedes normal cell proliferation. Thus, it explains published seemingly contradictory positive or negative regulatory activity of MLL/MLL fusion in cell proliferation (Muyrers-Chen et al. 2004; Milne et al. 2005; Xia et al. 2005; Takeda et al. 2006). Furthermore, MLL degradation signals through its N-terminal ~1400 amino acids, which are universally retained in MLL leukemia fusions. Importantly, tested prevalent MLL fusions—including MLL-AF4, MLL-AF9, MLL-ENL, and MLL-ELL, and leukemogenic MLL-lacZ—all exhibit diminished interaction with Skp2 and Cdc20, resulting in resistance to degradation mediated by the respective cell cycle UPS and a constant presence through the cell cycle phase transition. Here, we uncover a functional commonality among structurally diversified fusion partners and propose a model in which fusion partners interfere with the recognition of respective MLL fusions by the cell cycle E3 ligases, resulting in their nonoscillating expression. We

hypothesize that loss of the biphasic expression of MLL fusions represents the long-sought-after universal defect underlying all MLL leukemias. Complementary to our demonstrated MLL–E2F axis utilized by MLL in activating *Cyclin* expression, the current study recognizes a critical post-translational regulation of MLL by the cell cycle degradation machinery that is lost in MLL fusions.

Results

Biphasic expression of MLL through the cell cycle

To determine whether the activity of MLL, like other key cell cycle regulators, needs to be temporally regulated, we examined MLL protein expression through progressive phases of the cell cycle. HeLa cells were first synchronized at G1/S and early M phases with double thymidine and nocodazole, respectively, before being subjected to release for the indicated periods of time. Cells at distinct phases of the cell cycle were confirmed by fluorescence-activated cell sorter (FACS) analysis following propidium iodine (PI) staining for DNA contents (Fig. 1A,B, left panels) or by fluorescent microscopy (Fig. 1C). Remarkably, we uncovered a unique biphasic expression pattern of MLL protein when cells progressed through individual phases (Fig. 1A,B, right panels). Both N-terminal (MLL^{N320}) and C-terminal (MLL^{C180}) MLL fragments exhibited a coordinated expression pattern: down-regulation at S and late M phases following respective peaks at G1/S and G2/M transitions (Fig. 1A,B). The degradation of MLL in late M phase was further illustrated by fluorescent microscopy (Fig. 1C). The same biphasic expression pattern was observed in human embryonic kidney 293T cells and human osteosarcoma U2OS cells, irrespective of the synchronization techniques utilized, such as centrifugal elutriation and mimosine block (Supplementary Fig. S1; data not shown). These data unveil a previously unrecognized temporal regulation of MLL activity during the cell cycle progression.

MLL is degraded by the UPS during the cell cycle

To investigate the mechanism(s) underlying the biphasic expression of MLL, we examined the MLL mRNA level in cells at different phases of the cell cycle by quantitative RT-PCR (qRT-PCR). The amounts of MLL transcripts did not correlate with its protein levels (Fig. 2A), suggesting a dominating post-transcriptional control. As protein degradation constitutes the major post-translational control of cell cycle regulators, we examined whether cell cycle phase-specific degradation occurs. Immunoprecipitated Flag-MLL^{N320/C180} was incubated with cellular extracts purified from the indicated phases of the cell cycle in an attempt to recapitulate the *in vivo* degradation of MLL. Degradation of immunoprecipitated Flag-MLL^{N320/C180} was then monitored by anti-Flag immunoblots. MLL was degraded by extracts derived from S- and late M-phase cells but not from G1-, G2-, or early M-phase cells (Fig. 2B). These data indicate the utilization

of specialized degradation machinery in controlling MLL protein expression. Since a specialized UPS constitutes the major protein degradation machinery of the cell cycle, we tested whether the addition of MG132, a proteasome inhibitor, will increase the protein half-life of MLL in the presence of cycloheximide, which blocks translation. Indeed, a nearly eightfold extension of its half-life was observed (Fig. 2C). The cell cycle UPS marks proteins for degradation through polymerized ubiquitin conjugation. To determine whether MLL also undergoes UPS-mediated post-translational modifications, HA-Ubiquitin and Flag-MLL were coexpressed in cells followed by anti-Flag immunoprecipitation. Flag-MLL was covalently modified by HA-Ubiquitin and an increased abundance of the ubiquitin-modified high-molecular-weight MLL was observed when MG132 was added (Fig. 2D).

Specialized cell cycle E3 ligases mediate cognate degradation of MLL

The two major E3 complexes of UPS involved in degradation of core cell cycle regulators are SCF and APC complexes, the substrate recognition of which is conducted by the variable components—F-box proteins for SCF, and Cdc20 and Cdh1 for APC (Nakayama and Nakayama 2006). The bimodal degradation of MLL at S and late M phases suggests the involvement of both SCF and APC for respective degradation. We first examined whether overexpression of any of the major substrate recognition F-box proteins of SCF—including Fbw7, Skp2, and β TrCP—affects the expression of endogenous MLL. Among tested F-box proteins, only Skp2 enhanced the degradation of MLL (Fig. 3A). Similarly, Cdc20 but not Cdh1 degraded MLL *in vivo* (Fig. 3A). To determine whether Skp2 and Cdc20 directly target MLL for degradation, we probed the direct interactions between these two substrate recognition modules and MLL by coimmunoprecipitation assays in the presence of MG132. Indeed, direct intracellular interactions were identified between endogenous MLL and Skp2 as well as MLL and Cdc20 (Fig. 3B). In addition to the observed *in vivo* interactions, an *in vitro* degradation assay was employed to confirm the direct degradation of MLL^{N320/C180} by SCF^{Skp2} and APC^{Cdc20}. Protein lysates prepared from synchronized S- and late M-phase cells were incubated with equal amounts of immunoprecipitated Flag-MLL^{N320/C180} for 1 h at 30°C followed by anti-Flag Western blot analysis. Since protein modifications such as phosphorylation are known important signals required for substrate recognition/degradation by the cell cycle UPS, the utilization of immunoprecipitated Flag-MLL^{N320/C180} as test substrates abrogates the need for *in vitro* modifications before being subjected to *in vitro* degradation assays. Both S- and late M-phase lysates efficiently degraded Flag-MLL^{N320/C180} (Fig. 3C). Importantly, MLL degradation was impaired when SCF^{Skp2} and APC^{Cdc20} were immunodepleted, confirming the direct degradation of MLL^{N320/C180} at S and late M phases by SCF^{Skp2} and APC^{Cdc20}, respectively (Fig. 3C). These data demonstrate

Figure 1. Biphasic expression of MLL during cell cycle progression. (A) Double thymidine block and release of HeLa cells demonstrated two individual peaks of MLL expression. HeLa cells were synchronized at the G1/S transition by double thymidine block followed by the release into thymidine-free media for the indicated time. (B) Nocodazole block and release of HeLa cells identified the same two peak expressions of MLL as A. (A,B) The levels of MLL^{N320} and MLL^{C180} were determined with anti-NT and anti-CT immunoblots, respectively. (A,B, left panels) The successful synchronization and subsequent release from indicated chemical inhibitor was confirmed by FACS analyses of the DNA contents and by immunoblots using the anti-phospho-histone H3 Ser-10 antibody, which marks mitosis. (A,B) The expression of β-actin served as a loading control. (C) MLL protein is decreased at late M phase. Immunofluorescence studies were performed on asynchronous HeLa cells using anti-MLL (red) and anti-phospho-histone H3 S10 (green) antibodies. Individual phase assignments were based on nuclear morphology, with representative photos presented.

direct degradation of MLL by SCF^{Skp2} and APC^{Cdc20}, and predict an increase of MLL protein when the expression of Skp2 or Cdc20 is suppressed. To test this hypothesis, small interfering RNA (siRNA)-mediated knockdown of Skp2 and/or Cdc20 was performed to determine whether the MLL protein level is altered. Singular knockdown of Skp2 or Cdc20 led to an increase of the MLL level, and simultaneous knockdown of Skp2 and Cdc20 resulted in a robust ~3.5-fold increase of MLL^{C180} and a 1.7-fold increase of MLL^{N320}. The observed lesser increase of MLL^{N320} is likely due to the known poor gel

transfer of MLL^{N320} onto a membrane. Furthermore, it may also reflect the more unstable nature of the N-terminal MLL (Hsieh et al. 2003b). Taken together, our studies detail the blueprint underlying MLL degradation through the cell cycle, confirming SCF^{Skp2} and APC^{Cdc20} as two major E3 complexes in orchestrating MLL expression. Demonstrated regulation of MLL by the cell cycle UPS raises the possibility that the temporal necessity of MLL for gene activation is of quintessential importance in executing inherent programs for cell cycle progression.

DMSO vehicle for an additional 24 h. Cells were lysed in RIPA buffer containing 20 mM N-ethylmaleimide, which inhibits deubiquitination. Cellular extracts were subjected to anti-Flag immunoprecipitation, SDS-PAGE, and immunoblots with the indicated antibodies.

Concerted expression of MLL is necessary for proper cell cycle progression

In addition to our prior report, which indicates direct participation of MLL in the cell cycle gene expression program through the MLL-E2F axis (Takeda et al. 2006), our current data highlight a programmed regulation of the MLL level conferred by the cell cycle UPS. The next important questions are why the activity of MLL needs to be temporally controlled and whether deregulation of such an exquisite expression causes any cell cycle aberrations. To tackle these questions, RNA interference (RNAi)-mediated knockdown and overexpression of MLL were performed to interrogate possible cell cycle defects. Retrovirus-mediated stable knockdown of MLL in HeLa cells was performed, and the consequences of failed MLL induction at G1/S and G2/M transitions were examined. Two independent MLL-short hairpin RNA (shRNA) constructs stably reduced the expression of MLL as compared with the scramble shRNA (scr-shRNA) control (Fig. 4A; Supplementary Fig. S2). MLL knockdown cells were impaired in proliferation—a nearly twofold reduction of total cell number was observed after 6 d in culture (Fig. 4B; Supplementary Fig. S2). To specifically pinpoint the defect at G1/S transition, cells were synchronized by double thymidine treatment before being released into standard culture medium for the indicated periods of time. The S-phase entrance rate was

Figure 2. MLL undergoes bimodal degradation by the UPS. (A) The levels of MLL mRNA do not correlate with the biphasic MLL protein expression through specific phases of the cell cycle. qRT-PCR was performed on HeLa cells that were synchronized by double thymidine treatment and released for the indicated periods of time. MLL expression was normalized against GAPDH. The average MLL expression in asynchronous HeLa cells was arbitrarily assigned as 1.0. Values shown are mean $\pm$ 1 SD obtained from three independent experiments. (B) MLL is degraded at specific phases of the cell cycle. On-bead in vitro degradation assays were carried out by incubating purified Flag-MLL^{N320/C180} with cellular lysates prepared from cells synchronized at the indicated phases of the cell cycle for 30 min at 30°C. The abundance of Flag-MLL was analyzed by anti-Flag immunoblots. (C) The degradation of MLL can be prevented by inhibitors of the 26S proteasome. HeLa cells were treated with 10 μ M cycloheximide for the indicated periods of time in the presence of either DMSO as a control or 10 μ M MG132 to inactivate 26S proteasome. (Left panel) The expression of MLL was evaluated by anti-MLL immunoblots. The expression of β -actin served as a loading control. (Right panel) The half-life of MLL^{N320/C180} was determined by quantifying the levels of normalized MLL^{C180}. (D) MLL undergoes polyubiquitination. 293T cells transfected with indicated expression vectors for 48 h were treated with MG132 or

evaluated with a 30-min pulse of BrdU, which specifically labels active DNA synthesis. Strikingly, a 1-h delay in S-phase entry was observed in MLL-deficient cells (Fig. 4C), indicating that the G1/S peak of MLL is required for proper G1/S transition. We then examined the defect in M phase following the loss of the second MLL peak. MLL-deficient HeLa cells were synchronized with nocodazole in prometaphase before being released into standard culture medium for the indicated periods of time. Cellular DNA contents were stained with PI and analyzed by FACS. In MLL knockdown cells, the impaired G2/M peak expression resulted in a marked delay in M-phase progression (Fig. 4D,E). Thus, the up-regulation of MLL in G1/S and G2/M transitions is apparently required for S-phase entry and M-phase progression, respectively.

We next investigated why MLL needs to be degraded. In other words: What are the consequences if MLL continues to express at high levels? To answer this question, GFP-MLL was transiently overexpressed in 293T cells, the cell cycle profile of which was monitored by costaining with 7-AAD for DNA contents and BrdU for active DNA synthesis. An increased appearance (22.9%) of cells with an intermediate incorporation of BrdU was identified in GFP-MLL-expressing cells, suggestive of deterred replication (Fig. 4F). Taken together, these data emphasize the importance of the biphasic expression of MLL in coordinating the cell cycle progression.

Figure 3. The bimodal degradation of MLL is mediated by SCF^{Skp2} and APC^{Cdc20}. (A) Specialized substrate recognition modules (Skp2 and Cdc20) of the cell cycle E3 ligases are required for the degradation of MLL. Specific degradation of the endogenous MLL protein occurred in cells with overexpression of Skp2 or Cdc20. 293T cells were transfected with the indicated Myc-tagged substrate recognition module of cell cycle E3 ligases, and the levels of endogenous MLL were detected with the indicated anti-MLL antibodies. The level of β-actin served as a loading control. (B) MLL interacts with Skp2 and Cdc20 in vivo. Cellular lysates of 293T cells treated with MG132 were subjected to immunoprecipitation (IP) with anti-MLL antibody. Coprecipitated Skp2 and Cdc20 were detected by immunoblots. Protein-A beads served as a negative control. (C) In vitro degradation assays confirm the direct recognition and subsequent destruction of MLL by SCF^{Skp2} and APC^{Cdc20} in S and late M phases, respectively. Immunoprecipitated Flag-MLL was incubated with the indicated cellular lysates obtained from synchronized HeLa cells at 30°C for 30 min before being subjected to Western blot analyses. Anti-Skp2 or anti-Cdc20 immunoprecipitation was performed to deplete SCF^{Skp2} or APC^{Cdc20} from the indicated lysates. Mouse IgG was used as mock depletion. (D) Knockdown of Skp2 and/or Cdc20 leads to the accumulation of MLL protein. HeLa cells were transfected with the indicated siRNA specific for Skp2 or Cdc20. Protein levels of endogenous Skp2, Cdc20, and MLL were analyzed by Western blots at 72 h after transfection and quantified using ImageGauge software (FujiFilm). The level of β-actin served as a loading control, and the expression of MLL in control knockdown (siScr, si scramble) was arbitrarily assigned as 1.0.

The MLL N-terminal ~1400 amino acids target MLL^{N320/C180} for degradation

To further characterize how MLL degradation is regulated, the region responsible for the observed degradation was mapped. Flag-tagged constructs representing different regions of MLL were cotransfected with either Skp2 or Cdc20, followed by examinations of their expressions

by anti-Flag immunoblots (Fig. 5A). The first ~1400 amino acids of MLL were found to recapitulate the degradation of MLL^{N320/C180} (Fig. 5A). In contrast, MLL^{C180} alone was insensitive to degradation by coexpressed Skp2 or Cdc20 (Fig. 5A). As endogenous MLL^{FL} derived from proteolytic processing of MLL^{FL} precursor heterodimerizes with MLL^{N320} (Hsieh et al. 2003b) and is susceptible to degradation, it is possible that MLL^{C180} is degraded through its interaction with MLL^{N320}; i.e., MLL^{N320} brings heterodimerized MLL^{C180} to the 26S proteasome for degradation. To test this hypothesis, MLL^{N320} (amino acids 1–2664) and MLL^{C180} (amino acids 2772–3969) were cotransfected with or without specific E3 substrate recognition modules, Skp2 and Cdc20. In accordance with our data on the degradation of endogenous MLL^{N320/C180} (Fig. 3A), MLL^{C180} was degraded along with the cotransfected MLL^{N320} in the presence of either Skp2 or Cdc20 (Fig. 5B). If the MLL C terminus was degraded while complexed with MLL^{N320}, a MLL C-terminal mutant that no longer interacts with MLL^{N320} would be resistant to such a degradation. We employed a mutant MLL C terminus (MLL^{C180ΔF/SET}) that lacks FYRC and SET domains—a region that mediates its heterodimerization with MLL^{N320} (Hsieh et al. 2003b). When Flag-MLL^{C180ΔF/SET} (amino acids 2722–3620) was coexpressed with Flag-MLL^{N320} (amino acids 1–2664) plus either Myc-Skp2 or Myc-Cdc20, its level remained unchanged (Fig. 5B). This was in stark contrast to the nearly complete disappearance of Flag-MLL^{C180} (Fig. 5B). Thus far, our data establish a model in which the very N-terminal ~1400 amino acids of MLL are responsible for the coordinated biphasic control of MLL^{N320/C180}. Since all of the MLL leukemia fusions retain the degradation-prone region of MLL (Rowley 1998; Ayton and Cleary 2001; Canaani et al. 2004; Daser and Rabbitts 2004; Gilliland et al. 2004; Hess 2004), it is possible that the fusion partners confer resistance to degradation to initiate the first universal insult underlying all MLL leukemias.

MLL fusions are refractory to the cell cycle UPS, resulting in stable expression through the cell cycle

The findings that the common MLL N-terminal ~1400 amino acids are responsible for the degradation of MLL^{N320/C180} are consistent with our prior observation that MLL^{N320} is less stable (Hsieh et al. 2003b). These data rekindle a prior proposal that fusion partners may contribute to leukemogenesis in part by stabilizing the N-terminal MLL (Dobson et al. 2000; Hsieh et al. 2003b). We next examined whether leukemogenic MLL fusions are refractory to degradation. Indeed, tested prevalent MLL fusions, including MLL-AF4, MLL-AF9, MLL-ENL and MLL-ELL, were all resistant to SCF^{Skp2}- and APC^{Cdc20}-mediated degradation (Fig. 6A). Remarkably, the same resistance to degradation was also observed with the leukemogenic MLL-lacZ but not the nonleukemogenic MLL-Myc tag fusion (Fig. 6A). Subsequent experiments were performed to determine whether endogenous MLL fusions undergo cell cycle-coordinated

Figure 4. Deregulation of MLL protein level incurs corresponding cell cycle progression defects. (A) Stable knockdown of MLL in HeLa cells was achieved with shRNA against MLL. HeLa cells were infected with retrovirus-expressing shRNA targeting MLL (MLL-shRNA) or control scramble shRNA (Scr-shRNA). The successful suppression of MLL expression was confirmed by anti-MLL Western blots. (B) Depletion of MLL impairs cell proliferation. The proliferation curves of HeLa cells with or without MLL knockdown are provided. Replicate cultures of 10,000 cells were plated and trypsinized at the indicated time points to obtain cell numbers. Values shown are mean $\pm$ 1 SD obtained from three independent experiments. (C) A marked impairment in S-phase entry is observed in MLL knockdown cells. HeLa cells with or without MLL knockdown were synchronized at the G1/S transition by double thymidine block, followed by a release for the indicated time points. Cells were chased with BrdU for 30 min before collections, and S-phase entry was assessed by the positive BrdU staining determined by FACS. (D,E) MLL is required for proper M-phase progression. HeLa cells with MLL or control knockdown were synchronized at the prometaphase by nocodazole block plus shake-off procedure before being released into regular culture medium. Cells were stained with PI for DNA content before being subjected to FACS analyses to monitor phase progression of the cell cycle. Quantification of the M-phase progression from serial graphs presented in E is presented in D. (F) Overexpression of MLL induces an S-phase block. 293T cells were transfected with GFP-MLL or GFP-expressing plasmids for 48 h before being subjected to a 30-min BrdU pulse immediately before analyses. GFP-positive cells were gated for analyses of BrdU incorporation and DNA content. Additional controls using untransfected cells were included. (C–F) Results presented are representative data of three independent experiments.

degradation in various MLL leukemia cell lines. Interestingly, unlike commonly utilized tissue culture cell lines such as HeLa, 293T, and U2OS cells, we were unable to use mimosine, double thymidine, or nocodazole to synchronize available MLL leukemia cells, including MLL-AF4-bearing SEM and RS(4;11) and MLL-AF9-bearing THP-1, NOMO-1, and MOLM13 cell lines. This surprising observation suggests inherent cell cycle defects of these MLL leukemia cells. One possible scenario is that these cells have cycle checkpoint defects that confer resistance to chemical-induced synchronization. Nevertheless, individual populations representing distinct phases of the cell cycle were separated using centrifugal elutriation based on their physical properties. The purity of each population was assessed by FACS analysis of DNA contents (Fig. 6B). Remarkably, we witnessed a loss of the unique biphasic expression of MLL-AF4 in SEM human MLL leukemia cells (Fig. 6B). In contrast to the biphasic expression of wild-type MLL, MLL-AF4 protein did not fluctuate through the cell cycle while its level was not markedly increased (Fig. 6B). As overexpression of MLL fusion is likely to block cell cycle

progression and induce apoptosis (Muyrers-Chen et al. 2004; Xia et al. 2005), additional compensatory mechanism(s) must have evolved to maintain the level of MLL fusions within a tolerable range. Since all of the MLL fusions contain the common N-terminal ~1400 amino acids that signal degradation, it is possible that individual fusion partners directly interfere with the recognition of the MLL N terminus by the cell cycle E3 ligases. Coimmunoprecipitation assays were performed in cells transfected with indicated Flag-MLL fusions to examine this hypothesis. Indeed, diminished interactions between tested MLL fusions and endogenous Skp2 or Cdc20 were observed (Fig. 6C). To further demonstrate the refractoriness of MLL fusions to the cell cycle UPS, *in vitro* degradation assays were performed on immunoprecipitated MLL-AF4. In contrast to the nearly complete degradation of MLL by S- or late M-phase extracts, no significant degradation of MLL-AF4 was observed (Fig. 6D). In conclusion, we discovered a common defect associated with all of the tested prevalent MLL fusions that were not previously appreciated. The resistance of MLL fusions to preprogrammed degradation likely con-

Liu et al.

Figure 5. The MLL N terminus is responsible for the degradation of MLL^{N320/C180}. (A) The N-terminal 1400 amino acids of MLL are targeted by SCF^{Skp2} and APC^{Cdc20} for degradation. Various Flag-MLL fragments were coexpressed in 293T cells with either Myc-Skp2 or Myc-Cdc20. The protein levels of various MLL fragments were determined by anti-Flag Western blots. The diagram on the right depicts the domain compositions of transfected MLL fragments. Flag-MLL(1–3969) served as a positive control. (B) MLL^{N320} brings MLL^{C180} to degradation. Flag-MLL^{N320} plus Flag-MLL^{C180} or Flag-MLL^{N320} plus Flag-MLL^{C180ΔF/SET} were coexpressed in 293T cells with either Myc-Skp2 or Myc-Cdc20 before being subjected to indicated Western blot analyses.

stitutes the first universal insult committed by all MLL fusions, leading to the ultimate development of frank MLL leukemias.

Discussion

MLL and the cell cycle machinery

MLL, the mammalian homolog of *Drosophila trithorax*, is best known for its positive regulation of *Hox* gene expression. Homozygous disruption of *MLL* in mice results in early embryonic lethality, and heterozygous deficiency results in *homeotic* transformation due to impaired maintenance of *Hox* genes (Yu et al. 1995). The early lethality of *MLL*^{−/−} mouse embryos precludes detailed investigation of its involvement in other signaling pathways. Our demonstration that MLL is regulated by Taspase1-mediated proteolytic cleavage broadens the avenue in studying MLL in that noncleaved precursor MLL functions as a hypomorphic allele. Although the underlying mechanisms were not further investigated, initial characterizations on *MLL*^{−/−} mice suggest a role of MLL

Figure 6. MLL fusions are resistant to SCF^{Skp2}- or APC^{Cdc20}-mediated degradation. (A) Prevalent MLL fusion proteins, including MLL-AF4, MLL-AF9, MLL-ENL, and MLL-ELL, and leukemogenic MLL-lacZ, are resistant to Skp2- or Cdc20-mediated degradation. Various Flag-tagged MLL fusions were coexpressed in 293T cells with Myc-Skp2 or Myc-Cdc20. The levels of MLL fusions were analyzed by anti-Flag immunoblots. (B) Human MLL leukemia cell line SEM t(4;11) exhibits constant expression of endogenous MLL-AF4 protein through the cell cycle progression. (Bottom panel) To examine the expression of MLL-AF4, we synchronized the cells with centrifugal elutriation and confirmed individual phases of the cell cycle with PI staining of the DNA content followed by FACS analyses. The same amounts of lysates purified from indicated cellular fractions were subjected to immunoprecipitation with anti-AF4 antibody, which recognizes the C terminus of AF4. Immunoprecipitates were resolved by SDS-PAGE and analyzed with an anti-MLL antibody (Bethyl Laboratories) that recognizes amino acids 720–780 of MLL. (C) Fusion partners interfere with the recognition of MLL N terminus by Skp2 and Cdc20. Flag-MLL fusions and Flag-MLL(1–1400) were transfected in 293T cells for 2 d, followed by treatment with MG132 for 4 h. Cellular extracts were subjected to anti-Flag immunoprecipitation assays. Immunoprecipitates were analyzed by Western blots using anti-Flag, anti-Skp2, and anti-Cdc20 antibodies. The abundance of coprecipitated endogenous Skp2 and Cdc20 was determined with anti-Skp2 and anti-Cdc20 Western blots, respectively. Immunoprecipitation with extracts prepared from untransfected cells or Flag-MLL(1–1400) transfected cells served as negative and positive controls, respectively. (D) MLL-AF4 is resistant to degradation by S- or late M-phase lysates. Flag-MLL-AF4 was transiently expressed in 293T cells and purified with anti-Flag antibody. Immunoprecipitated Flag-MLL-AF4 was aliquoted and subjected to in vitro degradation experiments using the indicated cellular lysates. The abundance of Flag-MLL-AF4 was then determined by anti-Flag Western blots.

in proliferation in addition to differentiation. For example, *MLL*^{-/-} fetal liver or yolk sac hematopoietic cells grow more slowly and form smaller colonies in methylcellulose assays (Hess et al. 1997). Our subsequent studies on cells deficient for *Taspase1* or bearing noncleavable alleles of *MLL* (*MLL*^{NC/NC}) recognized a participation of MLL through E2Fs in regulating cell proliferation (Takeda et al. 2006). The active involvement of MLL/trx in the cell cycle is conserved through evolution, in that genetic studies in *Drosophila* also highlighted a significant role of trx in cell proliferation (Muyrers-Chen et al. 2004). Recent studies, including ours, began to elucidate the downstream targets for MLL in the cell cycle regulation that include *Cyclins* and *CDKs* (Muyrers-Chen et al. 2004; Milne et al. 2005; Xia et al. 2005). We demonstrated a MLL–E2F axis in regulating *Cyclin E/A/B* expression for progressive cell cycle phase transition (Takeda et al. 2006). Here, we further investigated the participation of MLL in the cell cycle control and discovered a tightly controlled biphasic expression of MLL. This unique expression is conferred by defined windows of degradation mediated by specialized cell cycle E3 ligases: SCF^{Skp2} and APC^{Cdc20} (Fig. 7A). Importantly, individual peak expressions of MLL precede the induction of *Cyclin E/A* and *Cyclin B* to ensure proper G1/S transition and M-phase progression, respectively (Fig. 7A). Deregulation of this unique expression of MLL by shRNA-mediated knockdown causes corresponding defects in G1/S entry and M-phase progression (Fig. 7B). Furthermore, overexpression of MLL incurs specific S-phase defects, indicating the importance of down-regulating its activity in S phase (Fig. 7C). However, whether this resulted from sustained expression of *Cyclin E/A* and/or invoked not-yet-identified insults remains to be determined. Our data highlight the significance of this biphasic expression of MLL in regulating cell proliferation and uncover a novel mechanism in regulating MLL through protein degradation—another post-translational regulatory scheme in addition to *Taspase1*-mediated site-specific proteolysis. As MLL directly activates the transcription of *Cyclins* that exhibit periodic expression during cell proliferation, it is necessary for a cell to incorporate MLL expression into the intricately assembled cell cycle circuitry to ensure correct transition of progressive phases. Current data not only consolidate the role of MLL in activating cell cycle but also discover a built-in program elegantly designed to turn off MLL with an impeccable temporal sequence.

MLL leukemia

The observed undesirable cell cycle consequences from perturbations of MLL levels led us to postulate that MLL fusions may also interfere with the cell cycle—a mechanism that is not fully appreciated in MLL leukemogenesis. Human chromosome 11q23 aberrations disrupt *MLL*, leading to infant and chemotherapy-related leukemias. These balanced translocations fuse the N-terminal ~1400 amino acids of MLL in-frame with a wide spectrum of fusion partners to generate leukemogenic MLL

Figure 7. Models depict a critical biphasic expression of MLL through cell cycle progression, the consequences of its deregulation, and the resistance of MLL fusions to degradation. (A) MLL protein oscillates throughout the cell cycle with two distinct peaks at the G1/S and G2/M transitions. This unique expression was conferred by a bimodal degradation executed by SCF^{Skp2} and APC^{Cdc20} at S and late M phases, respectively. (B) Cells with constitutively low expression of MLL have defects in S-phase entry and M-phase progression. (C) Constitutively high expression of MLL incurs an S-phase block. (D) In human MLL leukemia cells, MLL fusions remain constant through the cell cycle due to their impaired interactions with Skp2 and Cdc20. This deregulated expression may represent the first initial biological insult contributing to the ultimate development of MLL leukemias.

fusions. Mysteriously, among the >60 diverse fusion partners identified so far, there are no commonly shared characteristics identified based on sequence or structure homology (Rowley 1998; Ayton and Cleary 2001; Canaani et al. 2004; Daser and Rabbitts 2004; Gilliland et al. 2004; Hess 2004). Genetic evidence provided by studying mice carrying individual MLL fusions reveals several fundamental aspects of MLL leukemias. First, the fusion partner is indispensable (Corral et al. 1996; Dobson et al. 2000). Second, the fusion partner can be as nonspecific as bacterial galactosidase (lac Z) in that mice bearing *MLL-lacZ* developed myeloid leukemia after a prolonged latency (Dobson et al. 2000). Third, the fusion partner determines the phenotypes of the resulting leukemia (Corral et al. 1996; Wang et al. 2005; Chen et al. 2006). For example, mice carrying *MLL-AF4* or *MLL-AF9* develop lymphoid versus myeloid malignancies (Corral et al. 1996; Chen et al. 2006; Metzler et al. 2006), mimicking human counterparts. Detailed analyses of individual MLL fusions using retrovirus-mediated gene

transduction of the hematopoietic stem cells provide insightful mechanistic explanations regarding MLL leukemias. These studies established important models, such as transactivation and dimerization (Slany et al. 1998; Martin et al. 2003; So et al. 2003). However, these two models can only explain subsets of MLL leukemias since not all fusion partners contain transactivation or dimerization domains. As mice bearing *MLL-lacZ* developed leukemia, it had long been postulated that lacZ induces leukemia through either oligomerizing or stabilizing the N terminus of MLL—two non-mutually exclusive mechanisms. Although stabilization may contribute to MLL leukemogenesis, it has not been further examined. Our initial studies on the site-specific proteolysis of MLL indicated that proteolytic cleavage of MLL is not only required for its full activation but also regulates its stability (Hsieh et al. 2003a,b; Takeda et al. 2006). Interestingly, Taspase1-mediated site-specific proteolysis also controls the protein levels of another recently identified Taspase1 substrate, TFIIA (transcription factor II A) (Hoiby et al. 2004; Zhou et al. 2006). As our prior studies implicated that MLL N terminus is unstable, we envisioned that fusion partners must stabilize the common MLL N terminus for downstream gene regulation (Hsieh et al. 2003b). Based on our current observations that levels of MLL need to be tightly monitored during cell proliferation and the degradation of MLL^{N320/C180} signals through its N-terminal ~1400 amino acids (the common denominator present in all MLL fusions), we hypothesize that deregulated expression of MLL fusions through cell division may constitute the long-awaited universal insult underlying all MLL leukemias. To interrogate this model, we examined whether overexpression of SCF^{Skp2} and APC^{Cdc20} affects the levels of leukemogenic MLL fusions, including MLL-AF4, MLL-AF9, MLL-ENL, MLL-ELL, and MLL-lacZ. Remarkably, our in vivo and in vitro degradation assays demonstrated that these MLL fusions, unlike MLL^{N320/C180}, have acquired resistance to specialized cell cycle UPS. Furthermore, when the human t(4;11) MLL leukemia cell line, SEM, was examined, we witnessed a constant expression of MLL-AF4 throughout progressive phases of the cell cycle. Although the consequences of stable expression of MLL fusions through the cell cycle progression remain to be determined, several studies focused on individual MLL fusions such as MLL-AF4 and MLL-AF9 did report associated cell cycle defects (Pession et al. 2003; Caslini et al. 2004; Xia et al. 2005). Most interestingly, we noticed that all of the five tested human MLL leukemia cell lines failed to be synchronized by drugs like mimosine, thymidine, and nocodazole, implicating global defects in cell cycle checkpoints. As shown in several knock-in murine MLL leukemia models—including MLL-AF4 (Chen et al. 2006; Metzler et al. 2006), MLL-AF9 (Corral et al. 1996), MLL-lacZ (Dobson et al. 2000), MLL-ELL (Luo et al. 2002), and MLL-CBP (Wang et al. 2005)—engineered mice only developed leukemia after a long latency or the challenge with carcinogens such as ENU (Luo et al. 2002; Wang et al. 2005), suggesting that MLL fusion alone is necessary but insufficient in MLL leukemogenesis.

Therefore, additional mutations are likely to contribute to the full-blown MLL leukemia phenotypes (Felix et al. 1998; Mahgoub et al. 1998; Armstrong et al. 2003; Oguchi et al. 2003). The loss of the biphasic expression of MLL fusions may initiate the first universal mechanistic insult toward the ultimate development of MLL leukemias by disrupting cell cycle checkpoints (Fig. 7D). Future studies focusing on dissecting the mechanisms by which MLL fusions compromise cell cycle checkpoints and evaluating the contribution of such defects in MLL leukemogenesis will certainly provide therapeutic vantage points in treating this deadly illness.

The intertwined relationship between PcG and trxG members in cell fate and cell cycle

Deregulation of essential developmental pathways commonly leads to dire outcomes, including cancer; the PcG and trxG proteins are such examples (van Lohuizen 1999). Initial genetic evidence obtained from flies along with subsequent studies in mammals established the fundamental roles of PcG and trxG proteins in maintaining *Hox* gene expression, thus ensuring the correct installment of complex body plans in higher organisms. In addition to their essential roles in embryonic development, deregulated PcG and trxG proteins also contribute to various oncogenic processes. For example, Bmi-1, a PcG protein, is well recognized for its ability to accelerate Myc-induced lymphoma in mice (van Lohuizen et al. 1991). Subsequent studies on Bmi-1-associated oncogenesis primarily emphasized the ability of Bmi-1 to suppress the expression of tumor suppressors p16^{ink4a} and ARF, thus promoting cancer cell proliferation (Jacobs et al. 1999b). Despite the well-established role in *Hox* gene regulation, the significance of Bmi-1-induced *Hox* gene alterations in Bmi-1-mediated oncogenesis remains undetermined. On the contrary, studies on MLL, the founder of trxG proteins, and its associated leukemias recognized the potential mechanistic importance of overexpression of *Hox* genes including *HoxA7*, *HoxA9*, and *HoxA11* in leukemogenesis (Armstrong et al. 2002; Ayton and Cleary 2003). However, whether aberrant cell cycle gene expression contributes to MLL leukemogenesis has not been largely questioned. Based on our findings that link MLL/MLL fusions to cell cycle regulation, we propose that a simultaneous deregulation of differentiation and proliferation through *Hox* and cell cycle genes by Bmi-1 and MLL is of paramount importance in respective carcinogenesis.

Materials and methods

Plasmid constructions, siRNA, and transfections

cDNAs encoding full-length MLL, various MLL fragments, and MLL fusions were fused in-frame after an N-terminal Flag tag (pCMV-3xFlag; Sigma) to generate individual eukaryotic expression constructs for transient transfection assays. Full-length Fbw7, Skp2, βTrCP1, Cdc20, and Cdh1 were cloned from a 293T cDNA library and inserted into an N-terminal Myc tag ex-

pression vector (CMV-Myc; Clontech). The pMT123 plasmid encoding HA-Ubiquitin was kindly provided by Dr. Dirk Bohmann (Treier et al. 1994). Lipofectamine and Oligofectamine (Invitrogen) were used to transfect plasmid and siRNA oligos (Dharmacon), respectively, according to the manufacturers' protocols. siRNA oligos against Skp2 (M-003324-03) and Cdc20 (M-003225-03) were purchased from Dharmacon.

Antibodies and Western blots

Anti-CT (C terminus) antibody that recognizes the transactivation domain of MLL^{C180} has been described previously (Hsieh et al. 2003b). A rabbit polyclonal anti-NT (N terminus) antibody (MO-353) was raised against amino acids 1600–1985 of MLL. Western blots using commercially available antibodies against Skp2 (Santa Cruz Biotechnology), Cdc20 (Santa Cruz Biotechnology), Myc (Santa Cruz Biotechnology), phospho-Histone H3 (Ser-10) (Upstate Biotechnology), MLL1 (recognizing amino acids 720–780 of MLL; Bethyl Laboratories), β -Actin (Sigma), Flag (Sigma), and HA (12CA5) were performed according to the manufacturers' recommendations. Antibodies were detected using the enhanced chemiluminescence method (Western Lightning, PerkinElmer). Western blot signals were acquired with the LAS-3000 Imaging system (FujiFilm) and were analyzed by ImageGauge software (FujiFilm) as described previously (Kim et al. 2006).

Immunofluorescence

HeLa cells were plated on LabTek II chamber slides (Nunc) overnight, washed with PBS twice, fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.2% Triton X-100 for 10 min, and blocked with 3% BSA in PBS for 1 h. These cells were subsequently incubated with the indicated primary antibodies for 3 h, followed by two PBS washes, and were then incubated with Alexa488-conjugated anti-mouse or Alexa568-conjugated anti-rabbit antibodies (Molecular Probes) for an additional 30 min. The nuclei were counterstained with Hoechst 33342 (Molecular Probes). Fluorescent images were captured by a CCD camera (Diagnostic Instruments) attached to an Olympus IX51 microscope and were analyzed with the SPOT advanced software.

Cell culture and synchronization

HeLa and 293T cells were obtained from American Type Culture Collection and grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum, nonessential amino acids, L-glutamine, and penicillin/streptomycin. The human leukemia cell line SEM, carrying the t(4;11)(q21;q23) chromosomal translocation, was maintained in RPMI 1640 medium (Invitrogen) containing the same supplements. For double thymidine block and release experiments, HeLa cells were treated with 2 mM thymidine for 12 h and released for 12 h, followed by the second 12-h treatment before being released into thymidine-free medium for the indicated periods of time. As to the nocodazole block and release experiments, HeLa cells were blocked with 200 ng/mL nocodazole for 18 h. Mitotic cells were enriched by shake-off and washed twice with PBS before being released into nocodazole-free medium for the indicated time. Centrifugal elutriation was carried out using a Beckman JE6B elutriation rotor (Beckman). Small aliquots of cells collected at indicated time points or fractions were subjected to FACS analysis of the DNA contents for cell cycle phase assignment before subsequent analyses.

qRT-PCR

Cells were harvested and lysed with Trizol (Invitrogen) for RNA purification using RNeasy (Qiagen). Reverse transcriptions were performed with oligo-dT plus random octamer primers (Ambion) using SuperScript II (Invitrogen). qPCR was performed with Power SYBR Green master mix (Applied Biosystems) in triplicate using the following MLL primer set: MLL-forward, ACACATTCCAGACCAAGAAACGAC, and MLL-reverse, AGGCATCTTCAATACTTTCTGCACAG. Data were acquired using an ABI PRISM 7000 system (Applied Biosystems) and analyzed as described previously (Takeda et al. 2006). GAPDH expression served as a control.

Cell cycle analyses and BrdU incorporation assays

Cells were trypsinized, washed with PBS, treated with 20 μ g/mL RNase A, and stained with 25 μ g/mL PI for 1 h before being subjected to cell cycle analyses. Flow-cytometric analyses were performed using a FACSCalibur flow cytometer (Becton-Dickinson) to measure DNA contents. Ten-thousand events were collected per each experiment, and the data were analyzed with FlowJo software (Tree Star) or FCS Express (De Novo System). Cells were pulsed with BrdU for 30 min and analyzed by FACSCalibur according to the manufacturer's manual (BD Pharmingen; FITC/APC BrdU Flow Kit).

shRNA-mediated knockdown of MLL in HeLa cells

Target sequences (GTGCCAAGCACTGTGCGAAA [Fig. 4] and (CTACCAACCCTAAACCCTG) [Supplementary Fig. S2]), against human MLL and a control scrambled sequence (GCGC GCTTTGTAGGATTTCG) that has no significant homology with the human genome were inserted into the pSUPER.retro.puro vector, according to the manufacturer's protocol (Oligoengine). Generated retrovirus carrying indicated shRNA was used to infect HeLa cells for 2 d before being subjected to puromycin selection at 2 μ g/mL.

Protein extracts and in vitro degradation assays

To obtain G1-phase lysates, HeLa cells were synchronized by mimosine for 16 h. For S-phase lysates, HeLa cells were synchronized by double thymidine block, followed by a 4-h release. To synchronize cells at G2 phase, HeLa cells were released from a double thymidine block for 5 h, followed by a 5-h treatment with 0.5 μ M etoposide and extensive washes to remove mitotic cells. As to early M-phase lysates, HeLa cells were synchronized at prometaphase by nocodazole treatment for 18 h. Cells released from the nocodazole block for 1 h were at late M phase. Synchronized cells were resuspended in buffer containing 20 mM Tris-HCl (pH 7.2), 2 mM dithiothreitol (DTT), 0.25 mM EDTA, and Complete Protease Inhibitor Cocktail (Roche) on ice before being transferred to a nitrogen disruption bomb (Parr). The pressure was subsequently brought up to 1000 psi, followed by incubation for 30 min on ice. The pressure was then slowly released to gently disrupt the cells. The homogenized materials were spun down at 10,000g for 10 min. The resulting cellular extracts were aliquoted and stored at -80°C . For immunodepletion experiments, 10 μ g of anti-Skp2 or anti-Cdc20 antibodies were first adsorbed to 15 μ L of protein-A beads (GE Healthcare) by rocking for 90 min at 4°C . The antibody-bound beads were washed and incubated with 40 μ L of HeLa extracts (~ 400 μ g of protein) for 2 h at 4°C . Bead-bound immunocomplexes were subsequently removed by centrifugation. Immunodepleted extracts were aliquoted and used for the indicated in vitro degra-

dation assays. 293T cells were transfected with the indicated Flag-MLL-expressing constructs for 2 d before being subjected to lysis with RIPA buffer in the presence of Complete Protease Inhibitor Cocktail (Roche). Expressed Flag-MLL was immunoprecipitated using anti-Flag M2 beads (Sigma). Bead-bound Flag-MLL was aliquoted for the indicated experiments. The degradation reaction (10 μ L) contained 40 mM Tris-HCl (pH 7.6), 5 mM $MgCl_2$, 1 mM DTT, 10% glycerol, 1 μ M ubiquitin aldehyde, 10 mM phosphocreatine, 100 μ g/mL creatine phosphokinase, 0.5 mM ATP, 10 μ g of the indicated HeLa cellular extracts, 3 μ L of Flag-MLL immunoprecipitates, and Complete Protease Inhibitor Cocktail (Roche). Following incubation for 1 h at 30°C, reactions were stopped by the addition of SDS sample buffer before being subjected to SDS-PAGE analyses.

Acknowledgments

We thank Drs. Scott Armstrong and Jorg Faber for providing human MLL leukemia cell lines. MLL-ENL and MLL-ELL expression constructs were kindly provided by Dr. Cleary and Dr. Mitani, respectively. H.L. is supported by NIH CA119008 to J.J.-D.H. E.H.-Y.C. is supported by the Searle Scholars Program, Mallinckrodt Jr. Foundation, NCI Howard Temin Award, and NIH CA125562. This work is supported by Mallinckrodt Jr. Foundation, ASH Scholar Award, NCI Howard Temin Award, and NIH CA119008 to J.J.-D.H.

References

- Armstrong, S.A., Staunton, J.E., Silverman, L.B., Pieters, R., den Boer, M.L., Minden, M.D., Sallan, S.E., Lander, E.S., Golub, T.R., and Korsmeyer, S.J. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. *Nat. Genet.* **30**: 41–47.
- Armstrong, S.A., Kung, A.L., Mabon, M.E., Silverman, L.B., Stam, R.W., Den Boer, M.L., Pieters, R., Kersey, J.H., Sallan, S.E., Fletcher, J.A., et al. 2003. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. *Cancer Cell* **3**: 173–183.
- Ayton, P.M. and Cleary, M.L. 2001. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. *Oncogene* **20**: 5695–5707.
- Ayton, P.M. and Cleary, M.L. 2003. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. *Genes & Dev.* **17**: 2298–2307.
- Blais, A. and Dynlacht, B.D. 2004. Hitting their targets: An emerging picture of E2F and cell cycle control. *Curr. Opin. Genet. Dev.* **14**: 527–532.
- Bracken, A.P., Ciro, M., Cocito, A., and Helin, K. 2004. E2F target genes: Unraveling the biology. *Trends Biochem. Sci.* **29**: 409–417.
- Canaani, E., Nakamura, T., Rozovskaia, T., Smith, S.T., Mori, T., Croce, C.M., and Mazo, A. 2004. ALL-1/MLL1, a homologue of *Drosophila* TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia. *Br. J. Cancer* **90**: 756–760.
- Cardozo, T. and Pagano, M. 2004. The SCF ubiquitin ligase: Insights into a molecular machine. *Nat. Rev. Mol. Cell Biol.* **5**: 739–751.
- Caslini, C., Serna, A., Rossi, V., Introna, M., and Biondi, A. 2004. Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein. *Leukemia* **18**: 1064–1071.
- Chen, W., Li, Q., Hudson, W.A., Kumar, A., Kirchhof, N., and Kersey, J.H. 2006. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. *Blood* **108**: 669–677.
- Corral, J., Lavenir, I., Impey, H., Warren, A.J., Forster, A., Larson, T.A., Bell, S., McKenzie, A.N., King, G., and Rabbitts, T.H. 1996. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. *Cell* **85**: 853–861.
- Daser, A. and Rabbitts, T.H. 2004. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. *Genes & Dev.* **18**: 965–974.
- Djabali, M., Selleri, L., Parry, P., Bower, M., Young, B., and Evans, G.A. 1993. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. *Nat. Genet.* **4**: 431.
- Dobson, C.L., Warren, A.J., Pannell, R., Forster, A., and Rabbitts, T.H. 2000. Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. *EMBO J.* **19**: 843–851.
- Domer, P.H., Fakharzadeh, S.S., Chen, C.S., Jockel, J., Johansen, L., Silverman, G.A., Kersey, J.H., and Korsmeyer, S.J. 1993. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. *Proc. Natl. Acad. Sci.* **90**: 7884–7888.
- Dyson, N. 1998. The regulation of E2F by pRB-family proteins. *Genes & Dev.* **12**: 2245–2262.
- Eguchi, M., Eguchi-Ishimae, M., and Greaves, M. 2005. Molecular pathogenesis of MLL-associated leukemias. *Int. J. Hematol.* **82**: 9–20.
- Felix, C.A., Megonigal, M.D., Chervinsky, D.S., Leonard, D.G., Tsuchida, N., Kakati, S., Block, A.M., Fisher, J., Grossi, M., Salhany, K.I., et al. 1998. Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. *Blood* **91**: 4451–4456.
- Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. *Oncogene* **25**: 5220–5227.
- Gilliland, D.G., Jordan, C.T., and Felix, C.A. 2004. The molecular basis of leukemia. *Hematology* **2004**: 80–97.
- Gu, Y., Nakamura, T., Alder, H., Prasad, R., Canaani, O., Cimino, G., Croce, C.M., and Canaani, E. 1992. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to *Drosophila* trithorax, to the AF-4 gene. *Cell* **71**: 701–708.
- Guo, W.J., Datta, S., Band, V., and Dimri, G.P. 2007. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. *Mol. Biol. Cell* **18**: 536–546.
- Hanson, R.D., Hess, J.L., Yu, B.D., Ernst, P., van Lohuizen, M., Berns, A., van der Lugt, N.M., Shashikant, C.S., Ruddle, F.H., Seto, M., et al. 1999. Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. *Proc. Natl. Acad. Sci.* **96**: 14372–14377.
- Hershko, A. 2005. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. *Cell Death Differ.* **12**: 1191–1197.
- Hess, J.L. 2004. Mechanisms of transformation by MLL. *Crit. Rev. Eukaryot. Gene Expr.* **14**: 235–254.
- Hess, J.L., Yu, B.D., Li, B., Hanson, R., and Korsmeyer, S.J. 1997. Defects in yolk sac hematopoiesis in Mll-null embryos. *Blood* **90**: 1799–1806.
- Hoiby, T., Mitsiou, D.J., Zhou, H., Erdjument-Bromage, H., Tempst, P., and Stunnenberg, H.G. 2004. Cleavage and proteasome-mediated degradation of the basal transcription factor TFIIA. *EMBO J.* **23**: 3083–3091.
- Hsieh, J.J., Cheng, E.H., and Korsmeyer, S.J. 2003a. Taspase1: A threonine aspartase required for cleavage of MLL and

- proper HOX gene expression. *Cell* **115**: 293–303.
- Hsieh, J.J., Ernst, P., Erdjument-Bromage, H., Tempst, P., and Korsmeyer, S.J. 2003b. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. *Mol. Cell. Biol.* **23**: 186–194.
- Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. 1999a. The oncogene and Polycomb-group gene *bmi-1* regulates cell proliferation and senescence through the *ink4a* locus. *Nature* **397**: 164–168.
- Jacobs, J.J., Scheijen, B., Voncken, J.W., Kieboom, K., Berns, A., and van Lohuizen, M. 1999b. *Bmi-1* collaborates with *c-Myc* in tumorigenesis by inhibiting *c-Myc*-induced apoptosis via *INK4a/ARF*. *Genes & Dev.* **13**: 2678–2690.
- Khan, J.A., Dunn, B.M., and Tong, L. 2005. Crystal structure of human Taspase1, a crucial protease regulating the function of MLL. *Structure* **13**: 1443–1452.
- Kim, H., Rafiuddin-Shah, M., Tu, H.C., Jeffers, J.R., Zambetti, G.P., Hsieh, J.J., and Cheng, E.H. 2006. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. *Nat. Cell Biol.* **8**: 1348–1358.
- Luo, R.T., Kebriaei, P., Kaberlein, J.J., and Thirman, M.J. 2002. Cooperating mutations are necessary for the development of AML in *mll-ELL* knock-in mice. *Blood* **100**: 136a.
- Mahgoub, N., Parker, R.I., Hosler, M.R., Close, P., Winick, N.J., Masterson, M., Shannon, K.M., and Felix, C.A. 1998. RAS mutations in pediatric leukemias with MLL gene rearrangements. *Genes Chromosomes Cancer* **21**: 270–275.
- Martin, M.E., Milne, T.A., Bloyer, S., Galoian, K., Shen, W., Gibbs, D., Brock, H.W., Slany, R., and Hess, J.L. 2003. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. *Cancer Cell* **4**: 197–207.
- Martinez, A.M. and Cavalli, G. 2006. The role of polycomb group proteins in cell cycle regulation during development. *Cell Cycle* **5**: 1189–1197.
- Martinez, A.M., Colomb, S., Dejardin, J., Bantignies, F., and Cavalli, G. 2006. Polycomb group-dependent Cyclin A repression in *Drosophila*. *Genes & Dev.* **20**: 501–513.
- Metzler, M., Forster, A., Pannell, R., Arends, M.J., Daser, A., Lobato, M.N., and Rabbitts, T.H. 2006. A conditional model of MLL-AF4 B-cell tumorigenesis using invertebrate technology. *Oncogene* **25**: 3093–3103.
- Milne, T.A., Briggs, S.D., Brock, H.W., Martin, M.E., Gibbs, D., Allis, C.D., and Hess, J.L. 2002. MLL targets SET domain methyltransferase activity to Hox gene promoters. *Mol. Cell* **10**: 1107–1117.
- Milne, T.A., Hughes, C.M., Lloyd, R., Yang, Z., Rozenblatt-Rosen, O., Dou, Y., Schnepf, R.W., Krankel, C., Livolsi, V.A., Gibbs, D., et al. 2005. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. *Proc. Natl. Acad. Sci.* **102**: 749–754.
- Morgan, D.O. 1997. Cyclin-dependent kinases: Engines, clocks, and microprocessors. *Annu. Rev. Cell Dev. Biol.* **13**: 261–291.
- Murray, A.W. 2004. Recycling the cell cycle: Cyclins revisited. *Cell* **116**: 221–234.
- Muyers-Chen, I., Rozovskaia, T., Lee, N., Kersey, J.H., Nakamura, T., Canaani, E., and Paro, R. 2004. Expression of leukemic MLL fusion proteins in *Drosophila* affects cell cycle control and chromosome morphology. *Oncogene* **23**: 8639–8648.
- Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T., Wassell, R., Dubois, G., Mazo, A., Croce, C.M., and Canaani, E. 2002. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. *Mol. Cell* **10**: 1119–1128.
- Nakayama, K.I. and Nakayama, K. 2006. Ubiquitin ligases: Cell-cycle control and cancer. *Nat. Rev. Cancer* **6**: 369–381.
- Nevins, J.R. 2001. The Rb/E2F pathway and cancer. *Hum. Mol. Genet.* **10**: 699–703.
- Nurse, P. 2000. A long twentieth century of the cell cycle and beyond. *Cell* **100**: 71–78.
- Oguchi, K., Takagi, M., Tsuchida, R., Taya, Y., Ito, E., Isoyama, K., Ishii, E., Zannini, L., Delia, D., and Mizutani, S. 2003. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. *Blood* **101**: 3622–3627.
- Pession, A., Martino, V., Tonelli, R., Beltrami, C., Locatelli, F., Biserni, G., Franzoni, M., Freccero, F., Montemurro, L., Pattacini, L., et al. 2003. MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells. *Oncogene* **22**: 8671–8676.
- Peters, J.M. 2006. The anaphase promoting complex/cyclosome: A machine designed to destroy. *Nat. Rev. Mol. Cell Biol.* **7**: 644–656.
- Reed, S.I. 2003. Ratchets and clocks: The cell cycle, ubiquitylation and protein turnover. *Nat. Rev. Mol. Cell Biol.* **4**: 855–864.
- Ringrose, L. and Paro, R. 2004. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. *Annu. Rev. Genet.* **38**: 413–443.
- Rowley, J.D. 1998. The critical role of chromosome translocations in human leukemias. *Annu. Rev. Genet.* **32**: 495–519.
- Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B., and Cavalli, G. 2007. Genome regulation by polycomb and trithorax proteins. *Cell* **128**: 735–745.
- Schumacher, A. and Magnuson, T. 1997. Murine Polycomb- and trithorax-group genes regulate homeotic pathways and beyond. *Trends Genet.* **13**: 167–170.
- Sherr, C.J. and Roberts, J.M. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. *Genes & Dev.* **13**: 1501–1512.
- Slany, R.K., Lavau, C., and Cleary, M.L. 1998. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. *Mol. Cell. Biol.* **18**: 122–129.
- So, C.W., Lin, M., Ayton, P.M., Chen, E.H., and Cleary, M.L. 2003. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. *Cancer Cell* **4**: 99–110.
- Takeda, S., Chen, D.Y., Westergaard, T.D., Fisher, J.K., Rubens, J.A., Sasagawa, S., Kan, J.T., Korsmeyer, S.J., Cheng, E.H., and Hsieh, J.J. 2006. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. *Genes & Dev.* **20**: 2397–2409.
- Thirman, M.J., Gill, H.J., Burnett, R.C., Mbangkollo, D., McCabe, N.R., Kobayashi, H., Ziemann-van der Poel, S., Kaneko, Y., Morgan, R., Sandberg, A.A., et al. 1993. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. *N. Engl. J. Med.* **329**: 909–914.
- Tkachuk, D.C., Kohler, S., and Cleary, M.L. 1992. Involvement of a homolog of *Drosophila* trithorax by 11q23 chromosomal translocations in acute leukemias. *Cell* **71**: 691–700.
- Treier, M., Staszewski, L.M., and Bohmann, D. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain. *Cell* **78**: 787–798.
- Trimarchi, J.M. and Lees, J.A. 2002. Sibling rivalry in the E2F family. *Nat. Rev. Mol. Cell Biol.* **3**: 11–20.
- van Lohuizen, M. 1999. The trithorax-group and polycomb-group chromatin modifiers: Implications for disease. *Curr. Opin. Genet. Dev.* **9**: 355–361.

Liu et al.

- van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A. 1991. Identification of cooperating oncogenes in E μ -myc transgenic mice by provirus tagging. *Cell* **65**: 737–752.
- Wang, J., Iwasaki, H., Krivtsov, A., Febbo, P.G., Thomer, A.R., Ernst, P., Anastasiadou, E., Kutok, J.L., Kogan, S.C., Zinkel, S.S., et al. 2005. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. *EMBO J.* **24**: 368–381.
- Xia, Z.B., Popovic, R., Chen, J., Theisler, C., Stuart, T., Santillan, D.A., Erfurth, F., Diaz, M.O., and Zeleznik-Le, N.J. 2005. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. *Proc. Natl. Acad. Sci.* **102**: 14028–14033.
- Yokoyama, A., Kitabayashi, I., Ayton, P.M., Cleary, M.L., and Ohki, M. 2002. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. *Blood* **100**: 3710–3718.
- Yu, B.D., Hess, J.L., Horning, S.E., Brown, G.A., and Korsmeyer, S.J. 1995. Altered Hox expression and segmental identity in Mll-mutant mice. *Nature* **378**: 505–508.
- Yu, B.D., Hanson, R.D., Hess, J.L., Horning, S.E., and Korsmeyer, S.J. 1998. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. *Proc. Natl. Acad. Sci.* **95**: 10632–10636.
- Zhou, H., Spicuglia, S., Hsieh, J.J., Mitsiou, D.J., Hoiby, T., Veenstra, G.J., Korsmeyer, S.J., and Stunnenberg, H.G. 2006. Uncleaved TFIIA is a substrate for caspase 1 and active in transcription. *Mol. Cell. Biol.* **26**: 2728–2735.

Bimodal degradation of MLL by SCF^{Skp2} and APC^{Cdc20} assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions

Han Liu, Emily H.-Y. Cheng and James J.-D. Hsieh

Genes Dev. 2007, **21**:

Access the most recent version at doi:[10.1101/gad.1574507](https://doi.org/10.1101/gad.1574507)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2007/10/01/21.19.2385.DC1>

References

This article cites 72 articles, 21 of which can be accessed free at:
<http://genesdev.cshlp.org/content/21/19/2385.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).